Cargando…

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR

In hepatolithiasis, chronic proliferative cholangitis (CPC), an active and longstanding inflammation of stone-containing bile ducts with enhanced mucin-producing activity, not only affects the progression of the disease, it can also induce biliary carcinogenesis. The present study aimed to examine t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, San-Hu, Chen, Xue-Fang, Xie, Zhi-Bin, Zhou, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559293/ https://www.ncbi.nlm.nih.gov/pubmed/31115490 http://dx.doi.org/10.3892/ijmm.2019.4190

Ejemplares similares

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008)

Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab
por: Milenic, Diane E., et al.
Publicado: (2017)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
por: Yang, Zu-Yao, et al.
Publicado: (2012)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
por: Kaneko, Mika K., et al.
Publicado: (2018)

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
por: Cai, Wen-Qi, et al.
Publicado: (2020)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab
por: Wang, Aidong, et al.
Publicado: (2016)

Correction: modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies
por: Gelfo, Valerio, et al.
Publicado: (2019)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine
por: Baba, Yuji, et al.
Publicado: (2017)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations
por: Zheng, Qingmei, et al.
Publicado: (2022)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
por: Ottaiano, Alessandro, et al.
Publicado: (2013)

Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis
por: Lesma, Elena, et al.
Publicado: (2015)

KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
por: Morales-Estevez, Cristina, et al.
Publicado: (2016)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
por: James, Roshan, et al.
Publicado: (2012)

Downregulation of LRIG2 expression inhibits angiogenesis of glioma via EGFR/VEGF-A pathway
por: Yang, Hong-Kuan, et al.
Publicado: (2017)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial
por: Zhou, Quan, et al.
Publicado: (2021)

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
por: Smyth, Elizabeth C, et al.
Publicado: (2021)

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management
por: Abdullah, Shaad E., et al.
Publicado: (2012)

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
por: Bonomi, P D, et al.
Publicado: (2018)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits
por: Yang, Qin, et al.
Publicado: (2018)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
por: Jiang, Zheng, et al.
Publicado: (2013)

Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents
por: Park, Noh Jin, et al.
Publicado: (2013)

Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
por: Jones, Sylwia, et al.
Publicado: (2020)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
por: Melosky, B., et al.
Publicado: (2009)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rm1k5f41v8oecdp4adq1cl1tap